Novel immunotherapy agent safe, shows promise against high-risk prostate cancers
byJohns Hopkins University School of MedicinePatient consort diagram and efficacy outcomes in the neoadjuvant treatment of patients with PCa using enoblituzumab. Credit:Nature Medicine&nbs
Updated on: January 15,2024
20

Novel immunotherapy agent safe, shows promise against high-risk prostate cancers
byJohns Hopkins University School of MedicinePatient consort diagram and efficacy outcomes in the neoadjuvant treatment of patients with PCa using enoblituzumab. Credit:Nature Medicine&nbs
Updated on:January 15,2024
20
